Clinical trial

An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study

Aliases

NCT06609226, NN7535-7822

Name

NN7535-7822

Description

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.

Trial arms

Trial start

2024-11-15

Estimated PCD

2029-11-30

Trial end

2029-11-30

Status

Not yet recruiting

Phase

Early phase I

Treatment

Etavopivat A

Participants will receive an oral dose of Etavopivat A.

Arms:

Participants greater than or equal to (≥) 12 years old with sickle cell disease, Participants ≥ 11 months to less than (<) 12 years old with sickle cell disease, Participants ≥ 12 years old with non-transfusion dependent thalassaemia, Participants ≥ 12 years old with sickle cell disease on chronic red blood cell (RBC) transfusions, Participants ≥ 12 years old with transfusion-dependent thalassaemia

Etavopivat B

Participants will receive an oral dose of Etavopivat B.

Arms:

Participants ≥ 11 months to less than (<) 12 years old with sickle cell disease

Size

325

Primary endpoint

Number of treatment emergent adverse events (TEAEs), reported for each indication and age group separately

Baseline (week 0 of FLORAL) to end of study (week 264, or earlier)

Number of adverse reactions, reported for each indication and age group separately

Baseline (week 0 of FLORAL) to end of study (week 264, or earlier)

Eligibility criteria

Inclusion Criteria: * Participant must have ongoing participation in an etavopivat parent study for treatment of sickle cell disease (SCD) or thalassaemia and have completed at least a treatment period of the parent study. * Participant must have derived clinical benefit from treatment with etavopivat, as determined by the investigator. * Any participant with dose reduction or temporary discontinuation will need to be rechallenged before transferring. * Participants on hydroxyurea (HU), crizanlizumab or l-glutamine oral powder (Endari®) treatment at the time of consent may be eligible if they: * Have been on a stable dose during participation in the parent study (i.e., no changes to the dose except for changes to weight or age reasons). * Have been compliant with the treatment regimen at the discretion of the investigator during participation of the parent study. Exclusion Criteria: * Any disorder, except for conditions associated with SCD or thalassaemia, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Participant withdrew or had permanent treatment discontinuation from an etavopivat clinical study. * Participants on permanent dose reduction or temporary treatment discontinuation. * Use of any of the following within the timeframes prior to the transfer visit as stated: * Use of voxelotor within participation of the parent study or anticipated need for this agent during this study. * Use of an experimental selectin antagonist (e.g., monoclonal antibody or small molecule) within the parent study or anticipated need for such agents during this study. * Use of erythropoietin or other haematopoietic growth factor treatment within the parent study or anticipated need for such agents during this study. * Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4 within 2 weeks of the transfer visit or anticipated need for such agents during the study. * Current participation in a study that is not a designated parent study, or planned participation in any other clinical trial, for the duration of FLORAL.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 325, 'type': 'ESTIMATED'}}

Updated at

2024-09-24

1 organization

1 product

2 indications

Organization

Product

Indication

Indication